This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. Grubb, M.D.,
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aortic valve complex. Specifically, 14.2%
The optimal management of concomitant chronic obstructive coronary artery disease (CAD) in transcatheter aortic valve replacement (TAVR) recipients remains a debated topic. While some advocate for pre-TAVR percutaneous coronary intervention, others adopt an expectant approach. Original article: Persits I et al.
Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
The study, leveraging data from the STS Adult Cardiac Surgery Database (ACSD), offers the most comprehensive analysis to date of prosthetic valve outcomes, encompassing over 100,000 patients. The study addressed a critical question in cardiac surgery: how age and valve type influence outcomes for patients undergoing surgical AVR.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves.
Small aortic annulus poses a major challenge in aortic valve replacement due to the increased risk of prosthesispatient mismatch (PPM) and increased surgical risk. In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a popular alternative to the traditional surgical aortic valve replacement.
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc., Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4
TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. Researchers randomly assigned half of the participants to undergo TAVR and the other half to SAVR.
Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported it has reached a significant milestone of performing over 5,000 transcatheter aortic valve replacement (TAVR) procedures, the first in New Jersey and among the first to accomplish this in the United States.
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many. If their transcatheter heart valve degenerates later in life, most will hope to undergo redo-TAVR.
Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer. vs 74.7%, p=0.50).
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR).
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.
Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates. The post SAVR’s Value in the TAVR Era appeared first on Cardiac Wire.
What are the hemodynamic and clinical outcomes after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis (AS) and a small aortic annulus?
Tricuspid Valve Repair Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results. SAVR after TAVR Surgical aortic valve replacement after prior TAVR is the fastest-growing cardiac surgery procedure in the U.S.
What are outcomes among patients younger than 65 years who received transcatheter aortic valve replacement (TAVR) using a balloon-expandable valve compared to patients aged 65-80 years?
Among patients undergoing transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve (BEV), what are the 3-year clinical outcomes associated with a small (20 mm) compared to a larger (≥23 mm) device, and is there a relationship between the discharge echocardiographic (echo) mean gradient (MG) and measured or predicted thresholds (..)
Does measured or predicted prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR) affect all-cause mortality at 2 years?
This cohort study examines whether there is an association between osteosarcopenia and adverse outcomes, such as increased risk of mortality, in older adults following transcatheter aortic valve replacement (TAVR).
What are the contemporary characteristics, trends, and outcomes of intravascular lithotripsy (IVL)-assisted transfemoral (TF) transcatheter aortic valve replacement (TAVR) in the United States?
In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 3.5%, p=0.80) between the redo-TAVR and native-TAVR populations.
We believe the tools, resources, and information shared at the meeting will provide the healthcare community with greater expertise to improve patient outcomes and also connect with their interventional cardiology colleagues,” said SCAI President George D. About 276,000 patients have undergone a TAVR procedure in the United States.
Is there a relationship between site-level volumes and outcomes for transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER)?
Two separate late-breaking clinical trials – EARLY TAVR and EVOLVED – presented at TCT 2024 explore whether early aortic valve intervention improves outcomes in patients with asymptomatic aortic stenosis (AS).
The EARLY TAVR trial results demonstrate that early transcatheter aortic valve implantation in patients with asymptomatic severe aortic stenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
Background Coronary artery disease (CAD) is a common finding in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Methods and results We retrospectively reviewed 1,487 consecutive TAVR cases performed at a single tertiary care medical center.
In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis. He then examines titration of medications after acute heart failure.
Transcatheter aortic valve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.
What is the relationship between diffusion-weighted magnetic resonance imaging (DW-MRI) total lesion number (TLN), individual lesion volume (ILV), and total lesion volume (TLV) with clinical stroke outcomes after transcatheter aortic valve replacement (TAVR)?
These findings suggest opportunities to enhance clinical practice and improve outcomes for Medicare patients undergoing esophagectomy for cancer. Using the Society of Thoracic Surgeons Adult Cardiac Surgery Database , the study covers adult patients who underwent cardiac surgery after an initial TAVR from January 2012 to March 2023.
The goal of the NOTION trial was to compare outcomes after transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in unselected patients with severe degenerative aortic stenosis.
This concept should be applied when managing older patients with severe aortic stenosis. Although left ventricular wall hypertrophy is expected in patients with aortic stenosis, it should not be assumed that this is caused only by aortic stenosis.
The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. The trial enrolled 716 patients who underwent TAVR at 83 international sites in North America, Europe and the Middle East.
Blog Global Differences in Managing Patients with Aortic Valve Disease KCummings Thu, 10/24/2024 - 09:42 Adult Cardiac All Members It is time to reconsider the management of Aortic valve Disease (AVD) across the world. The medical community wanted to jump on the Bandwagon and aggressively market TAVR for patients.
Objectives To understand the patient and hospital level drivers of the variation in surgical versus trascatheter aortic valve replacement (SAVR vs TAVR) for patients with aortic stenosis (AS) and to explore whether this variation translates into differences in clinical outcomes.
Background and aims Randomised controlled trials comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) were performed in highly selected populations and data regarding long-term secondary complications beyond mortality are scarce. All-cause mortality at 1 year (HR 1.21; 95% CI 1.02
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content